Literature DB >> 7736682

Podocytes loose their adhesive phenotype in focal segmental glomerulosclerosis.

E Kemeny1, M J Mihatsch, U Dürmüller, F Gudat.   

Abstract

Podocytes in focal segmental glomerulosclerosis (FSGS) show injury and focal detachment from the glomerular basement membrane (GBM). We studied by immunofluorescence and light microscopy the distribution of components involved in the integrin mediated adhesion of podocytes to the GBM in one case of recurrent idiopathic FSGS which developed in a renal transplant. Two major integrin and actin distribution patterns were observed in podocytes depending on the stage of the disease. Alpha 5 integrin subunit showed a gradual loss in early FSGS and became undetectable in advanced FSGS. Alpha 3 integrin subunit and the beta 3 subunit of the vitronectin receptor lost their polarized expression and could be detected intracellularly in early FSGS, while in advanced stage both integrin subunits were mostly basally polarized. In addition staining for alpha 3 was markedly decreased but enhanced for beta 3. Most of the podocytes in early FSGS showed significant loss of filamentous actin together with a nonpolarized distribution and a transient expression of the HAR/GP90 receptor. An altered matrix composition was also seen corresponding to the newly formed GBM. Based on these results we propose that podocytes loose their adhesive phenotype in early FSGS, which may contribute to the detachment of podocytes from the GBM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7736682

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

Review 1.  Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?

Authors:  Caroline B Marshall
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-31

Review 2.  Genetic causes of proteinuria and nephrotic syndrome: impact on podocyte pathobiology.

Authors:  Oleh Akchurin; Kimberly J Reidy
Journal:  Pediatr Nephrol       Date:  2014-03-02       Impact factor: 3.714

3.  Alterations in extracellular matrix components and integrins in patients with preeclamptic nephropathy.

Authors:  H Shiiki; T Nishino; H Uyama; T Kimura; K Nishimoto; T Hashimoto; Y Fujii; K Dohi
Journal:  Virchows Arch       Date:  1996-03       Impact factor: 4.064

4.  Urinary excretion of viable podocytes in health and renal disease.

Authors:  Stefanie U Vogelmann; W James Nelson; Bryan D Myers; Kevin V Lemley
Journal:  Am J Physiol Renal Physiol       Date:  2003-03-11

Review 5.  Serum suPAR in patients with FSGS: trash or treasure?

Authors:  Rutger J H Maas; Jeroen K J Deegens; Jack F M Wetzels
Journal:  Pediatr Nephrol       Date:  2013-03-21       Impact factor: 3.714

6.  Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis.

Authors:  Carole Henique; Guillaume Bollée; Xavier Loyer; Florian Grahammer; Neeraj Dhaun; Marine Camus; Julien Vernerey; Léa Guyonnet; François Gaillard; Hélène Lazareth; Charlotte Meyer; Imane Bensaada; Luc Legrès; Takashi Satoh; Shizuo Akira; Patrick Bruneval; Stefanie Dimmeler; Alain Tedgui; Alexandre Karras; Eric Thervet; Dominique Nochy; Tobias B Huber; Laurent Mesnard; Olivia Lenoir; Pierre-Louis Tharaux
Journal:  Nat Commun       Date:  2017-11-28       Impact factor: 14.919

7.  Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand.

Authors:  Osamu Ichii; Saori Otsuka-Kanazawa; Teppei Nakamura; Masaaki Ueno; Yasuhiro Kon; Weiping Chen; Avi Z Rosenberg; Jeffrey B Kopp
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

8.  Upregulation of α3β1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy.

Authors:  Kaichiro Sawada; Masao Toyoda; Noriko Kaneyama; Sawako Shiraiwa; Hitomi Moriya; Han Miyatake; Eitaro Tanaka; Naoyuki Yamamoto; Masaaki Miyauchi; Moritsugu Kimura; Takehiko Wada; Masafumi Fukagawa
Journal:  J Diabetes Res       Date:  2016-06-01       Impact factor: 4.011

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.